En el cuarto trimestre de 2025, el gigante farmacéutico reconocido por sus medicamentos para adelgazar, reportó ingresos de 19 mil 290 mdd

Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an infectious disease portfolio.

The deals give Lilly vaccines targeting shingles, bacterial pathogens, and Epstein-Barr virus as it expands beyond weight loss drugs

Lilly is making three acquisitions at once on Tuesday, for up to $3.8 billion total, to increase its presence in infectious disease. The pharma is buying Curevo, LimmaTech…

Eli Lilly is acquiring three small vaccine developers, expanding its work in infectious diseases and giving the field a boost.

The deals are part of Eli Lilly’s effort to expand into infectious disease research and development.

Via the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus.

GLP-1 riches are being repurposed to prevent infections.

Eli Lilly announced Tuesday that it is acquiring Curevo Inc., LimmaTech Biologics AG and Vaccine Company, Inc., in deals totaling nearly $4 billion.

En el cuarto trimestre de 2025, el gigante farmacéutico reconocido por sus medicamentos para adelgazar, reportó ingresos de 19 mil 290 mdd